Patents by Inventor Andrew George Capacci

Andrew George Capacci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NRF2 ACTIVATOR
    Publication number: 20240279197
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.
    Type: Application
    Filed: December 19, 2023
    Publication date: August 22, 2024
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS
    Publication number: 20240083900
    Abstract: Provided are compounds of Formula (I?): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 14, 2024
    Applicant: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Isaac Marx, Jürgen Schulz, George Vandeveer, Robin Prince, Marta Nevalainen, TeYu Chen, Zain Yousaf, Martin Himmelbauer, Vatee Pattaropong, John Howard Jones, Edward Yin-Shiang Lin, Felix Gonzalez Lopez de Turiso, Thomas Purgett, Andrew George Capacci, Simone Sciabola
  • BTK INHIBITORS
    Publication number: 20230121818
    Abstract: Provided are compounds of Formula (I?) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R8, R9, R11A, R11B, R12, Ri, Rii, A1, A2, Q1, Q2, Q3, X, W, and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 20, 2023
    Inventors: Bin Ma, Brian T. Hopkins, Isaac Marx, Jürgen Schulz, George Vandeveer, Robin Prince, Marta Nevalainen, TeYu Chen, Zain Yousaf, Andrew George Capacci
  • Tetrahydronaphthalene derivatives useful as Nrf2 activators
    Patent number: 11465963
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 11, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • NRF2 ACTIVATOR
    Publication number: 20220048884
    Abstract: Provided are compounds of Formula A or I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 17, 2022
    Inventors: Andrew George Capacci, Michael Dechantsreiter, Istvan Enyedy, John H. Jones, Edward Yin Shiang Lin, Brian Stuart Lucas, Bin Ma
  • NRF2 ACTIVATOR
    Publication number: 20210387960
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 16, 2021
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • NRF2 ACTIVATOR
    Publication number: 20210340107
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 4, 2021
    Inventors: Brian Stuart Lucas, Edward Yin Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
  • NRF2 activator
    Patent number: 10968181
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: April 6, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian Stuart Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
  • TETRAHYDRONAPHTHALENE DERIVATIVES USEFUL AS NRF2 ACTIVATORS
    Publication number: 20200299230
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 24, 2020
    Inventors: Andrew George Capacci, Edward Yin Shiang Lin, Brian Stuart Lucas
  • NRF2 ACTIVATOR
    Publication number: 20190389830
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 26, 2019
    Inventors: Andrew George Capacci, Edward Yin-Shiang Lin, Brian Stuart Lucas
  • NRF2 ACTIVATOR
    Publication number: 20190389836
    Abstract: Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Andrew George Capacci, Michael Dechantsreiter, Istvan Enyedy, John H. Jones, Edward Yin-Shiang Lin, Brian Stuart Lucas, Bin Ma
  • NRF2 ACTIVATOR
    Publication number: 20190345112
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: December 27, 2017
    Publication date: November 14, 2019
    Inventors: Brian Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten